Motohiko Oshima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Motohiko Oshima has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Iwama
The Institute of Medical Science, The University of Tokyo
7 shared publications - Shuhei Koide
Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan
5 shared publications - Yaeko Nakajima-Takagi
Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Tokyo, Japan
5 shared publications - Atsushi Kaneda
Department of Molecular Oncology, Graduate School of Medicine, Chiba University
4 shared publications - Bahityar Rahmutulla
Chiba University, Chiba, Japan
4 shared publications - Masayuki Yamashita
Division of Experimental Hematology, Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN
4 shared publications
Latest Publications
- 9 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (41)
Long-term immunoprophylaxis by TLR9 ligand mediates macrophage-ILC cross-talk against respiratory viral infection
Rapid development of host immunity is critical during the emergence of viral outbreaks when vaccines are not yet available. Here, we demonstrate that CpG oligodeoxynucleotide-schizophyllan complex (K3-SPG) induces antigen-independent, long-term protection against lethal respiratory virus infection. A single intranasal administration successfully enhanced host resistance to infection for as long as 100 days posttreatment. Mechanistically, we observed a lung-restricted biphasic innate activation of macrophages and innate lymphoid cells. Early protection was mediated by CD11b + CD11c + macrophages (DP MΦ) and monocyte-derived interstitial macrophages (IMΦ). Late protection was mediated by innate lymphoid cells that were epigenetically reprogrammed, suggesting that two distinct innate immune subsets contribute to the maintenance of disease tolerance in the lung microenvironment. Deficiency of TLR9 or TNF-α abrogated innate activation and protective immunity. Collectively, these findings demonstrate that adjuvant-induced prophylaxis is a promising approach to enhancing host resistance against respiratory virus infection, involving the biphasic cooperation between innate immune cells in the local tissue.
- 9 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (41)
Long-term immunoprophylaxis by TLR9 ligand mediates macrophage-ILC cross-talk against respiratory viral infection
Rapid development of host immunity is critical during the emergence of viral outbreaks when vaccines are not yet available. Here, we demonstrate that CpG oligodeoxynucleotide-schizophyllan complex (K3-SPG) induces antigen-independent, long-term protection against lethal respiratory virus infection. A single intranasal administration successfully enhanced host resistance to infection for as long as 100 days posttreatment. Mechanistically, we observed a lung-restricted biphasic innate activation of macrophages and innate lymphoid cells. Early protection was mediated by CD11b + CD11c + macrophages (DP MΦ) and monocyte-derived interstitial macrophages (IMΦ). Late protection was mediated by innate lymphoid cells that were epigenetically reprogrammed, suggesting that two distinct innate immune subsets contribute to the maintenance of disease tolerance in the lung microenvironment. Deficiency of TLR9 or TNF-α abrogated innate activation and protective immunity. Collectively, these findings demonstrate that adjuvant-induced prophylaxis is a promising approach to enhancing host resistance against respiratory virus infection, involving the biphasic cooperation between innate immune cells in the local tissue.
- 21 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (34)
Geneformer-guided multiomics integration identifies Pbx1 as a network hub of hematopoietic stem cell aging
Hematopoietic stem cells (HSCs) constitute an organized hematopoietic system that undergoes age-related alterations, including increased platelet production and decreased erythropoiesis. The fundamental mechanisms driving these shifts remain incompletely understood. We used single-cell RNA sequencing data to show that old HSCs contain two distinct transcriptional programs: one shared with megakaryocytes and the other reflecting the most primitive HSC state. Developmental time-series profiling further suggests that the acquisition of these programs begins early in life, with the primitive module rising prenatally and megakaryocytic priming emerging after birth. Using a fine-tuned Geneformer (transformer-based deep learning model) to capture higher-order differences between young and old HSCs, coupled with transcriptomic and epigenetic profiling, as well as transcription factor screens, we identified Pbx1 as a key regulator of these age-related transcriptional and differentiation changes. Specifically, Pbx1 suppresses erythroid differentiation by repressing Gata1 expression. These findings provide insight into HSC aging and may inform approaches to modulate age-associated HSC dysfunction.
- 21 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (34)
Geneformer-guided multiomics integration identifies Pbx1 as a network hub of hematopoietic stem cell aging
Hematopoietic stem cells (HSCs) constitute an organized hematopoietic system that undergoes age-related alterations, including increased platelet production and decreased erythropoiesis. The fundamental mechanisms driving these shifts remain incompletely understood. We used single-cell RNA sequencing data to show that old HSCs contain two distinct transcriptional programs: one shared with megakaryocytes and the other reflecting the most primitive HSC state. Developmental time-series profiling further suggests that the acquisition of these programs begins early in life, with the primitive module rising prenatally and megakaryocytic priming emerging after birth. Using a fine-tuned Geneformer (transformer-based deep learning model) to capture higher-order differences between young and old HSCs, coupled with transcriptomic and epigenetic profiling, as well as transcription factor screens, we identified Pbx1 as a key regulator of these age-related transcriptional and differentiation changes. Specifically, Pbx1 suppresses erythroid differentiation by repressing Gata1 expression. These findings provide insight into HSC aging and may inform approaches to modulate age-associated HSC dysfunction.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S9 from Identification of a CD138-Negative Therapy-Resistant Subpopulation in Multiple Myeloma with Vulnerability to Splicing Factor Inhibition
Supplementary Table S1: Patient information, Table S2: DEGs upregulated in CD138+ and CD138− MM cells detected in bulk RNA-seq, Table S3: DEGs in each cluster detected in scRNA-seq, Table S4: List of sgRNAs used in CRISPR/Cas9 screening, Table S5: List of candidate genes from CRISPR/Cas9 screening, Table S6: List of differential splicing events detected in bulk RNA-seq, Table S7: List of differential splicing events detected in scRNA-seq, Table S8: List of differential splicing events detected in RNA-seq of RBM39 KO and indisulam-treated AMO-1 cells, and Table S9: Primer sequences for amplification and sequencing of sgRNA regions, sgRNAs for CRISPR/Cas9 KO and RT-PCR primers to confirm splicing patterns.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S9 from Identification of a CD138-Negative Therapy-Resistant Subpopulation in Multiple Myeloma with Vulnerability to Splicing Factor Inhibition
Supplementary Table S1: Patient information, Table S2: DEGs upregulated in CD138+ and CD138− MM cells detected in bulk RNA-seq, Table S3: DEGs in each cluster detected in scRNA-seq, Table S4: List of sgRNAs used in CRISPR/Cas9 screening, Table S5: List of candidate genes from CRISPR/Cas9 screening, Table S6: List of differential splicing events detected in bulk RNA-seq, Table S7: List of differential splicing events detected in scRNA-seq, Table S8: List of differential splicing events detected in RNA-seq of RBM39 KO and indisulam-treated AMO-1 cells, and Table S9: Primer sequences for amplification and sequencing of sgRNA regions, sgRNAs for CRISPR/Cas9 KO and RT-PCR primers to confirm splicing patterns.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S10 from Identification of a CD138-Negative Therapy-Resistant Subpopulation in Multiple Myeloma with Vulnerability to Splicing Factor Inhibition
Fig. S1: Sub-fractionation of MM cells by flow cytometry, Fig. S2: Detection of clonal repertoire in MM subfractions, Fig. S3: Heterogeneity of MM cells and cell surface marker gene expression, Fig. S4: DEGs in CD138+ and sCD138− MM cells, Fig. S5: Single-cell RNA-seq analysis of MM cells, Fig. S6: Single-cell RNA-seq and VDJ-seq analysis of MM cells, Fig. S7: Aberrant splicing in therapy-resistant sCD138− MM cells, Fig. S8: Re-analysis of published scRNA-seq data of BM MNCs of MM patients, Fig. S9: Aberrant splicing induced by RBM39 inhibition, and Fig. S10: RBM39 overexpression serves as a therapeutic target.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S10 from Identification of a CD138-Negative Therapy-Resistant Subpopulation in Multiple Myeloma with Vulnerability to Splicing Factor Inhibition
Fig. S1: Sub-fractionation of MM cells by flow cytometry, Fig. S2: Detection of clonal repertoire in MM subfractions, Fig. S3: Heterogeneity of MM cells and cell surface marker gene expression, Fig. S4: DEGs in CD138+ and sCD138− MM cells, Fig. S5: Single-cell RNA-seq analysis of MM cells, Fig. S6: Single-cell RNA-seq and VDJ-seq analysis of MM cells, Fig. S7: Aberrant splicing in therapy-resistant sCD138− MM cells, Fig. S8: Re-analysis of published scRNA-seq data of BM MNCs of MM patients, Fig. S9: Aberrant splicing induced by RBM39 inhibition, and Fig. S10: RBM39 overexpression serves as a therapeutic target.
- 29 August 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (6) , 602-622
Identification of a CD138-Negative Therapy-Resistant Subpopulation in Multiple Myeloma with Vulnerability to Splicing Factor Inhibition
The molecular basis of therapy resistance in multiple myeloma remains poorly understood. In this study, we performed single-cell RNA sequencing coupled with VDJ-targeted sequencing of highly purified primary multiple myeloma cells from patient bone marrow. This approach uncovered cellular heterogeneity and phenotypic plasticity of multiple myeloma cells across a spectrum of CD138 expression, accompanied by drastic epigenetic alterations. Notably, therapy-resistant subpopulations were identified within a minor fraction of CD138– multiple myeloma cells, which were shown via CRISPR/Cas9 screening to be vulnerable to splicing pathway inhibition. Consistently, this fraction of CD138– multiple myeloma cells showed increased differential splicing associated with overexpression of SR protein family splicing factors. Among these splicing factors, RBM39 was overexpressed in therapy-resistant cells and involved in aberrant splicing. Both genetic and pharmacologic RBM39 inhibition exhibited a significant lethal effect on multiple myeloma cells. Collectively, our findings identify distinct therapy-resistant multiple myeloma subpopulations and highlight targeting the splicing pathway as a promising therapeutic strategy. Significance: Single-cell RNA sequencing coupled with VDJ-targeted profiling identified distinct therapy-resistant subpopulations within the minor CD138– fraction of multiple myeloma cells. These subpopulations were characterized by increased differential splicing events associated with overexpression of splicing factors from the SR protein family, with CD138− cells showing selective vulnerability to pharmacologic targeting of the splicing factor RBM39. See related commentary by Maron and Abdel-Wahab, p. 535
- 29 August 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (6) , 602-622
Identification of a CD138-Negative Therapy-Resistant Subpopulation in Multiple Myeloma with Vulnerability to Splicing Factor Inhibition
The molecular basis of therapy resistance in multiple myeloma remains poorly understood. In this study, we performed single-cell RNA sequencing coupled with VDJ-targeted sequencing of highly purified primary multiple myeloma cells from patient bone marrow. This approach uncovered cellular heterogeneity and phenotypic plasticity of multiple myeloma cells across a spectrum of CD138 expression, accompanied by drastic epigenetic alterations. Notably, therapy-resistant subpopulations were identified within a minor fraction of CD138– multiple myeloma cells, which were shown via CRISPR/Cas9 screening to be vulnerable to splicing pathway inhibition. Consistently, this fraction of CD138– multiple myeloma cells showed increased differential splicing associated with overexpression of SR protein family splicing factors. Among these splicing factors, RBM39 was overexpressed in therapy-resistant cells and involved in aberrant splicing. Both genetic and pharmacologic RBM39 inhibition exhibited a significant lethal effect on multiple myeloma cells. Collectively, our findings identify distinct therapy-resistant multiple myeloma subpopulations and highlight targeting the splicing pathway as a promising therapeutic strategy. Significance: Single-cell RNA sequencing coupled with VDJ-targeted profiling identified distinct therapy-resistant subpopulations within the minor CD138– fraction of multiple myeloma cells. These subpopulations were characterized by increased differential splicing events associated with overexpression of splicing factors from the SR protein family, with CD138− cells showing selective vulnerability to pharmacologic targeting of the splicing factor RBM39. See related commentary by Maron and Abdel-Wahab, p. 535
- Open Access
- 11 January 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (2) , 99-100
Sluggish FUS: a key for HSC aging
In this issue of Blood, Tang and colleagues report that the RNA-binding protein fused in sarcoma (FUS) is a newly identified effector of hematopoietic stem cell
- 11 January 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (2) , 99-100
Open AccessSluggish FUS: a key for HSC aging
In this issue of Blood, Tang and colleagues report that the RNA-binding protein fused in sarcoma (FUS) is a newly identified effector of hematopoietic stem cell
- Open Access
- 24 November 2020
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (3)
Limited rejuvenation of aged hematopoietic stem cells in young bone marrow niche
Hematopoietic stem cells (HSCs) exhibit functional alterations, such as reduced regenerative capacity and myeloid-biased differentiation, with age. The HSC niche, which is essential for the maintenance of HSCs, also undergoes marked changes with aging. However, it has been technically challenging to directly evaluate the contribution of niche aging to age-associated HSC alterations without niche-damaging myeloablation in HSC transplantation assays. We herein transplanted an excess of aged HSCs into young mice without preconditioning. Although aged HSCs successfully engrafted in the intact young bone marrow niche, they poorly regenerated downstream progenitors and exhibited persistent myeloid-biased differentiation, resulting in no significant functional rejuvenation. Transcriptome and methylome analyses revealed that the young niche largely restored the transcriptional profile of aged HSCs, but not their DNA methylation profiles. Therefore, the restoration of the young niche is insufficient for rejuvenating HSC functions, highlighting a key role for age-associated cell-intrinsic defects in HSC aging.
- 24 November 2020
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (3)
Open AccessLimited rejuvenation of aged hematopoietic stem cells in young bone marrow niche
Hematopoietic stem cells (HSCs) exhibit functional alterations, such as reduced regenerative capacity and myeloid-biased differentiation, with age. The HSC niche, which is essential for the maintenance of HSCs, also undergoes marked changes with aging. However, it has been technically challenging to directly evaluate the contribution of niche aging to age-associated HSC alterations without niche-damaging myeloablation in HSC transplantation assays. We herein transplanted an excess of aged HSCs into young mice without preconditioning. Although aged HSCs successfully engrafted in the intact young bone marrow niche, they poorly regenerated downstream progenitors and exhibited persistent myeloid-biased differentiation, resulting in no significant functional rejuvenation. Transcriptome and methylome analyses revealed that the young niche largely restored the transcriptional profile of aged HSCs, but not their DNA methylation profiles. Therefore, the restoration of the young niche is insufficient for rejuvenating HSC functions, highlighting a key role for age-associated cell-intrinsic defects in HSC aging.